Outlook Therapeutics, Inc.
OTLK· Nasdaq
Filed Dec 22, 2023 · 10-K · 83 days after period end · 0001558370-23-020000
derived · Computed from the longer spans the company filed.
| Metric | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures |
|---|---|---|---|---|
| Net Income | -$12.99M | -$14.35M | -$13.40M | -$9.92M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Outlook Therapeutics, Inc. · CIK 1649989 · Engraved from SEC EDGAR
ended Sep 30, 2023 · filed Dec 22, 2023 · 83 d after period end